Additionally, in vivo mouse models have been utilized to recapitulate this phenomenon by injecting lysate from individuals with tauopathies, recombinant tau fibrils, or lysate from transgenic mice into host mice with different genotypes to investigate the anatomical distribution of tau aggregation (Clavaguera et al., 2013; Narasimhan et al., 2017; He et al., 2020; Weitzman et al., 2020; Xu et al., 2021). This evidence concerns the gene MAPT and tauopathy.